New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
|Articles|April 1, 2016
Smart Sensors Now With Bluetooth
Advertisement
Hamilton’s intelligent Arc sensors can now be securely monitored, configured, and calibrated from your Bluetooth-enabled device. The unique ArcAir app includes protected user levels and a GMP compliance package for Android and iOS. The Arc system of online sensors eliminates costly, bulky transmitters. ArcAir is compatible with Hamilton’s pH, Dissolved Oxygen, ORP, and Conductivity Arc sensors.
INTERPHEX Booth # 3465
Advertisement
Related to this article
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Advertisement
Advertisement